New information on the death count from the covid 19 experimental shots.
As of July 21, 2021, the FDA had issued three Emergency Use Authorizations for COVID-19 vaccines. However, these experimental vaccines have not been approved by the FDA.
Also known as Endocarditis, Myocarditis, Pericarditis
Inflammation is your body’s response to infection or injury. It can affect many areas of the body and is a cause of many major diseases, including cancer, ischemic heart disease, and autoimmune diseases. Inflammation in the heart causes damage and can lead to serious health problems.
There are three main types of heart inflammation: endocarditis, myocarditis, and pericarditis. Endocarditis is inflammation of the inner lining of the heart’s chambers and valves. Myocarditis is inflammation of the heart muscle. Pericarditis is inflammation of the tissue that forms a sac around the heart. Many things cause heart inflammation. Common causes include viral or bacterial infections and medical conditions that damage the heart and cause inflammation.
You may have different signs and symptoms depending on the type and severity of the heart inflammation that you have. The treatment your doctor recommends may depend on whether you are diagnosed with inflammation of the lining of your heart or valves, the heart muscle, or the tissue surrounding the heart. You may be treated with medicine, procedures, or possibly surgery to treat your condition and its complications. Complications may include an arrhythmia, or irregular heartbeat, and heart failure.
For public awareness and in the interest of transparency, CDC is providing timely updates on the following serious adverse events of interest:
- Anaphylaxis after COVID-19 vaccination is rare and has occurred in approximately 2 to 5 people per million vaccinated in the United States. Severe allergic reactions, including anaphylaxis, can occur after any vaccination. If this occurs, vaccination providers can effectively and immediately treat the reaction. Learn more about COVID-19 vaccines and allergic reactions, including anaphylaxis.
- Thrombosis with thrombocytopenia syndrome (TTS) after Johnson & Johnson’s Janssen (J&J/Janssen) COVID-19 vaccination is rare. As of July 26, 2021, more than 13 million doses of the J&J/Janssen COVID-19 Vaccine have been given in the United States. CDC and FDA identified 39 confirmed reports of people who got the J&J/Janssen COVID-19 Vaccine and later developed TTS. Women younger than 50 years old especially should be aware of the rare but increased risk of this adverse event. There are other COVID-19 vaccine options available for which this risk has not been seen. Learn more about J&J/Janssen COVID-19 Vaccine and TTS.
- To date, two confirmed cases of TTS following mRNA COVID-19 vaccination (Moderna) have been reported to VAERS after more than 328 million doses of mRNA COVID-19 vaccines administered in the United States. Based on available data, there is not an increased risk for TTS after mRNA COVID-19 vaccination.
- CDC and FDA are monitoring reports of Guillain-Barré Syndrome (GBS) in people who have received the J&J/Janssen COVID-19 Vaccine. GBS is a rare disorder where the body’s immune system damages nerve cells, causing muscle weakness and sometimes paralysis. Most people fully recover from GBS, but some have permanent nerve damage. After more than 13 million J&J/Janssen COVID-19 Vaccine doses administered, there have been around 143 preliminary reports of GBS identified in VAERS as of July 30. These cases have largely been reported about 2 weeks after vaccination and mostly in men, many 50 years and older. CDC will continue to monitor for and evaluate reports of GBS occurring after COVID-19 vaccination and will share more information as it becomes available.
- Myocarditis and pericarditis after COVID-19 vaccination are rare. As of July 30, 2021, VAERS has received 1,249 reports of myocarditis or pericarditis among people ages 30 and younger who received COVID-19 vaccine. Most cases have been reported after mRNA COVID-19 vaccination (Pfizer-BioNTech or Moderna), particularly in male adolescents and young adults. Through follow-up, including medical record reviews, CDC and FDA have confirmed 716 reports of myocarditis or pericarditis. CDC and its partners are investigating these reports to assess whether there is a relationship to COVID-19 vaccination. Learn more about COVID-19 vaccines and myocarditis.
- Reports of death after COVID-19 vaccination are rare. More than 346 million doses of COVID-19 vaccines were administered in the United States from December 14, 2020, through August 2, 2021. During this time, VAERS received 6,490 reports of death (0.0019%) among people who received a COVID-19 vaccine. FDA requires healthcare providers to report any death after COVID-19 vaccination to VAERS, even if it’s unclear whether the vaccine was the cause. Reports of adverse events to VAERS following vaccination, including deaths, do not necessarily mean that a vaccine caused a health problem. A review of available clinical information, including death certificates, autopsy, and medical records, has not established a causal link to COVID-19 vaccines. However, recent reports indicate a plausible causal relationship between the J&J/Janssen COVID-19 Vaccine and TTS, a rare and serious adverse event—blood clots with low platelets—which has caused deaths.